Table 1. Characteristics of patients with SARS-CoV-2 positive in stool test.
| Characteristics | Overall, mean (SD)/No. (%) |
|---|---|
| Baseline | |
| Age, median (IQR), y | 53.00 (41.00–67.00) |
| Gender (male) | 5 (55.56%) |
| Wuhan exposure | 8 (88.89%) |
| Smoking | 5 (55.56%) |
| Hypertension | 2 (22.22%) |
| Diabetes | 1 (11.11%) |
| Cardiovascular disease | 0 (0%) |
| COPD | 1 (11.11%) |
| Malignancy | 0 (0%) |
| Chronic liver disease | 0 (0%) |
| Fever | 8 (88.89%) |
| Highest temperature, °C | 38.02±0.76 |
| Cough | 5 (55.56%) |
| Fatigue | 7 (77.78%) |
| Expectoration | 4 (44.44%) |
| Headache | 5 (55.56%) |
| Vomiting | 0 (0%) |
| Diarrhea | 3 (33.33%) |
| The onset of symptom to hospital admission, d | 6.56±3.61 |
| Systolic pressure, mmHg | 127.44±23.96 |
| Diastolic pressure, mmHg | 72.11±9.78 |
| Heart rate, per min | 91.44±13.31 |
| Respiratory rate, per min | 19.78±0.67 |
| SPO2, % | 96.56±1.13 |
| Laboratory testing | |
| White blood cell count, ×109/L | 5.22±2.69 |
| Red blood cell count, ×109/L | 4.34±0.87 |
| Neutrophil count, ×109/L | 3.75±2.64 |
| Lymphocyte count, ×109/L | 1.07±0.52 |
| Hemoglobin, g/L | 128.56±27.58 |
| Platelet count, ×109/L | 175.67±82.44 |
| Prothrombin time, s | 12.19±0.71 |
| Activated partial thromboplastin time, s | 33.59±3.28 |
| D-dimer, mg/L | 0.40±0.28 |
| Alanine aminotransferase, U/L | 29.15±11.01 |
| Aspartate aminotransferase, U/L | 26.69±10.36 |
| Albumin, g/L | 36.34±5.23 |
| Total bilirubin, mmol/L | 10.18±2.98 |
| Direct bilirubin, mmol/L | 3.32±1.05 |
| Serum K+, mmol/L | 4.05±0.63 |
| Serum Na+, mmol/L | 134.33±2.70 |
| Creatinine, ìmol/L (IQR) | 48.30 (44.77–63.37) |
| Blood urea nitrogen, mmol/L | 5.46±3.21 |
| Lactate dehydrogenase, U/L | 201.18±51.01 |
| Troponin T, <100 pg/mL | 9 (100%) |
| Creatine kinase, U/L | 114.74±110.40 |
| Creatine kinase–MB, U/L | 16.26±13.46 |
| Procalcitonin, ng/mL | 0.09±0.07 |
| C-reactive protein, mg/L | 31.27±20.04 |
| Cycle threshold of throat swab | 32.95±5.58 |
| Cycle threshold of stool | 33.68±4.46 |
| Chest CTs findings | |
| Unilateral pneumonia | 1 (11.11%) |
| Bilateral pneumonia | 5 (55.56%) |
| Multiple mottling and ground-glass opacity | 2 (22.22%) |
| Complications | |
| ARDS | 1 (11.11%) |
| Acute cardiac injury | 0 (0%) |
| AKI | 1 (11.11%) |
| Shock | 0 (0%) |
| Treatment | |
| Antiviral therapy | 9 (100.00%) |
| Antibiotic therapy | 3 (33.33%) |
| Use of corticosteroid | 3 (33.33%) |
| Probiotics | 7 (77.78%) |
| CRRT | 0 (0%) |
| Oxygen inhalation | |
| Nasal cannula | 7 (77.78%) |
| High flow | 2 (22.22%) |
| Outcomes | |
| Hospitalization | 7 (77.78%) |
| Discharge | 2 (22.22%) |
| Death | 0 (0%) |
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ND, not detected; CTs, computed tomography scan; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; CRRT, continuous renal replacement therapy.